Abstract

Obesity leads to chronic, systemic inflammation and can lead to insulin resistance (IR), β-cell dysfunction, and ultimately type 2 diabetes (T2D). This chronic inflammatory state contributes to long-term complications of diabetes, including non-alcoholic fatty liver disease (NAFLD), retinopathy, cardiovascular disease, and nephropathy, and may underlie the association of type 2 diabetes with other conditions such as Alzheimer's disease, polycystic ovarian syndrome, gout, and rheumatoid arthritis. Here, we review the current understanding of the mechanisms underlying inflammation in obesity, T2D, and related disorders. We discuss how chronic tissue inflammation results in IR, impaired insulin secretion, glucose intolerance, and T2D and review the effect of inflammation on diabetic complications and on the relationship between T2D and other pathologies. In this context, we discuss current therapeutic options for the treatment of metabolic disease, advances in the clinic and the potential of immune-modulatory approaches.

Keywords

InflammationObesityDiabetes mellitusBiologyBioinformaticsImmunologyInternal medicineEndocrinologyMedicine

MeSH Terms

AnimalsDiabetes ComplicationsDiabetes MellitusType 2HumansImmunomodulationInflammationInsulin ResistanceObesity

Affiliated Institutions

Related Publications

Publication Info

Year
2022
Type
review
Volume
55
Issue
1
Pages
31-55
Citations
1630
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1630
OpenAlex
32
Influential
1479
CrossRef

Cite This

Theresa V. Rohm, Daniel T. Meier, Jerrold M. Olefsky et al. (2022). Inflammation in obesity, diabetes, and related disorders. Immunity , 55 (1) , 31-55. https://doi.org/10.1016/j.immuni.2021.12.013

Identifiers

DOI
10.1016/j.immuni.2021.12.013
PMID
35021057
PMCID
PMC8773457

Data Quality

Data completeness: 90%